{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IIIB+Uterine+Sarcoma&page=2", "query": { "condition": "Stage IIIB Uterine Sarcoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IIIB+Uterine+Sarcoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T05:49:35.239Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00295945", "title": "Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cervical Cancer", "Endometrial Cancer", "Fallopian Tube Cancer", "Ovarian Cancer", "Pain", "Perioperative/Postoperative Complications", "Sarcoma" ], "interventions": [ { "name": "fentanyl citrate", "type": "DRUG" }, { "name": "hydromorphone hydrochloride", "type": "DRUG" }, { "name": "ropivacaine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 240, "start_date": "2005-03", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2014-05-20", "last_synced_at": "2026-05-22T05:49:35.239Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00295945" }, { "nct_id": "NCT01764802", "title": "Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Sarcoma", "Ovarian Stromal Cancer", "Stage I Uterine Sarcoma", "Stage I Vaginal Cancer", "Stage I Vulvar Cancer", "Stage IA Cervical Cancer", "Stage IA Endometrial Carcinoma", "Stage IA Fallopian Tube Cancer", "Stage IA Ovarian Epithelial Cancer", "Stage IA Ovarian Germ Cell Tumor", "Stage IA Primary Peritoneal Cavity Cancer", "Stage IB Cervical Cancer", "Stage IB Endometrial Carcinoma", "Stage IB Fallopian Tube Cancer", "Stage IB Ovarian Epithelial Cancer", "Stage IB Ovarian Germ Cell Tumor", "Stage IB Primary Peritoneal Cavity Cancer", "Stage IC Fallopian Tube Cancer", "Stage IC Ovarian Epithelial Cancer", "Stage IC Ovarian Germ Cell Tumor", "Stage IC Primary Peritoneal Cavity Cancer", "Stage II Endometrial Carcinoma", "Stage II Gestational Trophoblastic Tumor", "Stage II Uterine Sarcoma", "Stage II Vaginal Cancer", "Stage II Vulvar Cancer", "Stage IIA Cervical Cancer", "Stage IIA Fallopian Tube Cancer", "Stage IIA Ovarian Epithelial Cancer", "Stage IIA Ovarian Germ Cell Tumor", "Stage IIA Primary Peritoneal Cavity Cancer", "Stage IIB Cervical Cancer", "Stage IIB Fallopian Tube Cancer", "Stage IIB Ovarian Epithelial Cancer", "Stage IIB Ovarian Germ Cell Tumor", "Stage IIB Primary Peritoneal Cavity Cancer", "Stage IIC Fallopian Tube Cancer", "Stage IIC Ovarian Epithelial Cancer", "Stage IIC Ovarian Germ Cell Tumor", "Stage IIC Primary Peritoneal Cavity Cancer", "Stage III Gestational Trophoblastic Tumor", "Stage III Uterine Sarcoma", "Stage III Vaginal Cancer", "Stage III Vulvar Cancer", "Stage IIIA Cervical Cancer", "Stage IIIA Endometrial Carcinoma", "Stage IIIA Fallopian Tube Cancer", "Stage IIIA Ovarian Epithelial Cancer", "Stage IIIA Ovarian Germ Cell Tumor", "Stage IIIA Primary Peritoneal Cavity Cancer", "Stage IIIB Cervical Cancer", "Stage IIIB Endometrial Carcinoma", "Stage IIIB Fallopian Tube Cancer", "Stage IIIB Ovarian Epithelial Cancer", "Stage IIIB Ovarian Germ Cell Tumor", "Stage IIIB Primary Peritoneal Cavity Cancer", "Stage IIIC Endometrial Carcinoma", "Stage IIIC Fallopian Tube Cancer", "Stage IIIC Ovarian Epithelial Cancer", "Stage IIIC Ovarian Germ Cell Tumor", "Stage IIIC Primary Peritoneal Cavity Cancer", "Breast Cancer" ], "interventions": [ { "name": "behavioral, psychological or informational intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "21 Years to 80 Years · Female only" }, "enrollment_count": 100, "start_date": "2010-10", "completion_date": "2017-06-01", "has_results": false, "last_update_posted_date": "2018-05-30", "last_synced_at": "2026-05-22T05:49:35.239Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01764802" }, { "nct_id": "NCT05039801", "title": "IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Endometrial Carcinoma", "Advanced Head and Neck Squamous Cell Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Ovarian Clear Cell Adenocarcinoma", "Chondrosarcoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Recurrent Ovarian High Grade Serous Adenocarcinoma", "Refractory Endometrial Carcinoma", "Refractory Head and Neck Squamous Cell Carcinoma", "Refractory Melanoma", "Refractory Ovarian Clear Cell Adenocarcinoma", "Refractory Ovarian High Grade Serous Adenocarcinoma", "Stage III Ovarian Cancer AJCC v8", "Stage III Uterine Corpus Cancer AJCC v8", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIA Uterine Corpus Cancer AJCC v8", "Stage IIIA1 Ovarian Cancer AJCC v8", "Stage IIIA2 Ovarian Cancer AJCC v8", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIB Uterine Corpus Cancer AJCC v8", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IIIC Uterine Corpus Cancer AJCC v8", "Stage IIIC1 Uterine Corpus Cancer AJCC v8", "Stage IIIC2 Uterine Corpus Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Uterine Corpus Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Uterine Corpus Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Uterine Corpus Cancer AJCC v8" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Glutaminase-1 Inhibitor IACS-6274", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Capivasertib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2021-09-09", "completion_date": "2026-05-29", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-05-22T05:49:35.239Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05039801" }, { "nct_id": "NCT00253383", "title": "Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "counseling intervention", "type": "OTHER" }, { "name": "educational intervention", "type": "OTHER" }, { "name": "psychosocial assessment and care", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 329, "start_date": "2003-01", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2014-12-19", "last_synced_at": "2026-05-22T05:49:35.239Z", "location_count": 2, "location_summary": "Lebanon, New Hampshire • White River Junction, Vermont", "locations": [ { "city": "Lebanon", "state": "New Hampshire" }, { "city": "White River Junction", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT00253383" }, { "nct_id": "NCT00020579", "title": "MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "entinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2001-03", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-05-22T05:49:35.239Z", "location_count": 3, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020579" }, { "nct_id": "NCT01012297", "title": "Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Uterine Corpus Sarcoma", "Stage IIIA Uterine Sarcoma", "Stage IIIB Uterine Sarcoma", "Stage IIIC Uterine Sarcoma", "Stage IVA Uterine Sarcoma", "Stage IVB Uterine Sarcoma", "Uterine Corpus Leiomyosarcoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 107, "start_date": "2009-11", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2020-09-02", "last_synced_at": "2026-05-22T05:49:35.239Z", "location_count": 201, "location_summary": "Phoenix, Arizona • Burbank, California • Concord, California + 138 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01012297" }, { "nct_id": "NCT01367301", "title": "Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage IA Uterine Sarcoma", "Stage IB Uterine Sarcoma", "Stage IC Uterine Sarcoma", "Stage IIA Uterine Sarcoma", "Stage IIB Uterine Sarcoma", "Stage IIIA Uterine Sarcoma", "Stage IIIB Uterine Sarcoma", "Stage IIIC Uterine Sarcoma", "Stage IVA Uterine Sarcoma", "Stage IVB Uterine Sarcoma", "Uterine Carcinosarcoma" ], "interventions": [ { "name": "paclitaxel", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "external beam radiation therapy", "type": "RADIATION" }, { "name": "brachytherapy", "type": "RADIATION" }, { "name": "intensity-modulated radiation therapy", "type": "RADIATION" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER" ], "sponsor": "Albert Einstein College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 14, "start_date": "2011-07-08", "completion_date": "2018-08-15", "has_results": true, "last_update_posted_date": "2023-08-21", "last_synced_at": "2026-05-22T05:49:35.239Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01367301" }, { "nct_id": "NCT00445965", "title": "Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Intraocular Melanoma", "Lung Cancer", "Melanoma (Skin)", "Metastatic Cancer", "Neuroblastoma", "Ovarian Cancer", "Retinoblastoma", "Sarcoma", "Small Intestine Cancer" ], "interventions": [ { "name": "DNA analysis", "type": "GENETIC" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "iodine I 131 monoclonal antibody 3F8", "type": "RADIATION" }, { "name": "131I-3F8", "type": "RADIATION" } ], "intervention_types": [ "GENETIC", "OTHER", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 78, "start_date": "2006-01", "completion_date": "2023-02-01", "has_results": true, "last_update_posted_date": "2024-04-04", "last_synced_at": "2026-05-22T05:49:35.239Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00445965" }, { "nct_id": "NCT00003704", "title": "Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "1999-04", "completion_date": "2003-07", "has_results": false, "last_update_posted_date": "2016-07-06", "last_synced_at": "2026-05-22T05:49:35.239Z", "location_count": 17, "location_summary": "Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 14 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Cedar Rapids", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Sioux City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003704" }, { "nct_id": "NCT01522820", "title": "Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaplastic Astrocytoma", "Anaplastic Oligoastrocytoma", "Anaplastic Oligodendroglioma", "Estrogen Receptor Negative", "Estrogen Receptor Positive", "Glioblastoma", "Hormone-Resistant Prostate Cancer", "Metastatic Prostate Carcinoma", "Metastatic Renal Cell Cancer", "Recurrent Adult Brain Neoplasm", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Gastric Carcinoma", "Recurrent Hepatocellular Carcinoma", "Recurrent Lung Carcinoma", "Recurrent Melanoma", "Recurrent Ovarian Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Renal Cell Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Resectable Hepatocellular Carcinoma", "Sarcoma", "Stage IA Breast Cancer", "Stage IA Ovarian Cancer", "Stage IA Uterine Corpus Cancer", "Stage IB Breast Cancer", "Stage IB Ovarian Cancer", "Stage IB Uterine Corpus Cancer", "Stage IC Ovarian Cancer", "Stage II Uterine Corpus Cancer", "Stage IIA Breast Cancer", "Stage IIA Lung Carcinoma", "Stage IIA Ovarian Cancer", "Stage IIB Breast Cancer", "Stage IIB Esophageal Cancer", "Stage IIB Lung Carcinoma", "Stage IIB Ovarian Cancer", "Stage IIB Skin Melanoma", "Stage IIC Ovarian Cancer", "Stage IIC Skin Melanoma", "Stage IIIA Breast Cancer", "Stage IIIA Esophageal Cancer", "Stage IIIA Lung Carcinoma", "Stage IIIA Ovarian Cancer", "Stage IIIA Skin Melanoma", "Stage IIIA Uterine Corpus Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Esophageal Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Skin Melanoma", "Stage IIIB Uterine Corpus Cancer", "Stage IIIC Breast Cancer", "Stage IIIC Esophageal Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Skin Melanoma", "Stage IIIC Uterine Corpus Cancer", "Stage IV Bladder Urothelial Carcinoma", "Stage IV Esophageal Cancer", "Stage IV Ovarian Cancer", "Stage IV Prostate Cancer", "Stage IV Skin Melanoma", "Stage IVA Uterine Corpus Cancer", "Stage IVB Uterine Corpus Cancer" ], "interventions": [ { "name": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2012-03", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2016-10-04", "last_synced_at": "2026-05-22T05:49:35.239Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01522820" } ] }